SCHEMBL4270967

SCHEMBL4270967

Cc1nc(-c2ccc3c(c2)NC(=O)CO3)c(C)s1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 1/20 0.55
NR3C2 P08235 3/20 0.55
MMP12 P39900 1/20 0.55
KMT2A Q03164 1/20 0.54
KDM4E B2RXH2 4/20 0.53
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
POLB P06746 2/20 0.51
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PGR P06401 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286493 0.86 MAPT (0.58) MAPTALDH1A1HPGDNR3C2MMP12
SCHEMBL4262015 0.78 MMP12 (0.58) MAPTALDH1A1HPGDNR3C2MMP12
SCHEMBL19627036 0.78 ALDH1A1 (0.76) MAPTALDH1A1HPGDMMP12KMT2A
SCHEMBL19188055 0.76 MMP12 (0.77) MAPTALDH1A1HPGDNR3C2MMP12
SCHEMBL10662326 0.74 MAPT (0.62) MAPTALDH1A1HPGDMMP12KMT2A
SCHEMBL4261326 0.73 POLB (0.70) MAPTALDH1A1HPGDMMP12KMT2A
SCHEMBL4295289 0.73 MAPT (0.53) MAPTALDH1A1HPGDNR3C2KMT2A
SCHEMBL19625385 0.72 MAPT (0.71) MAPTALDH1A1HPGDMMP12KMT2A
SCHEMBL10653476 0.72 KDM4E (0.63) MAPTALDH1A1HPGDNR3C2MMP12
SCHEMBL10652983 0.72 KMT2A (0.54) MAPTALDH1A1HPGDNR3C2MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 MAPT 3273/4885ALDH1A1 3483/4885HPGD 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.